Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study

Santiago Escrivá-de-Romaní, Juan Miguel Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure, Marie-France Savard, Rossanna C. Pezo, Maria Gion, Manuel Ruíz‐Borrego, Erika Hamilton, Timothy Pluard, Marc Webster, Muralidhar Beeram, Hannah M. Linden, Cristina Saura, Diana Shpektor, Bob Salim, Phoebe Harvey, Sara A. Hurvitz